Consensus Legend Biotech Corporation

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 16/01/2026 GMT			5-day change	1st Jan Change
22.14 ^USD	+0.14%		-6.19%	+1.84%

01-14	Legend Biotech Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09:00 AM
01-12	Legend Biotech highlights recent business updates at 44th annual J.P. Morgan Healthcare conference	RE

Evolution of the Average Target: Legend Biotech Corporation

Evolution of the Target Price: Legend Biotech Corporation

Changes in Analyst Recommendations: Legend Biotech Corporation

403fb3f7d38b1cd6b3d868c12788db.XalZbUaR07-ZuSkoypA4FWTDGb2SS8UYWJ_oNYiToSw.F-MMIXbfmfXQwWFvudFoQxaVX8umCrBhF8CAT87AyBtr2jwEKdej-OH0cA~871ce5dd0deccde15df6903316ed1e68

Analysts' recommendations: Legend Biotech Corporation

01-08	RBC Cuts Price Target on Legend Biotech to $66 From $74, Keeps Outperform Rating	MT
01-07	Oppenheimer Initiates Legend Biotech at Outperform With $75 Price Target	MT
12-10	Legend Biotech's Stock Weakness After Rival Treatment Update 'Overdone,' RBC Says	MT
12-08	UBS Adjusts Legend Biotech Price Target to $48 From $54, Maintains Buy Rating	MT
11-13	RBC Trims Price Target on Legend Biotech to $74 From $75, Keeps Outperform Rating	MT
11-13	Truist Lowers Price Target on Legend Biotech to $70 From $71, Keeps Buy Rating	MT
08/10/25	RBC Trims Price Target on Legend Biotech to $75 From $77, Keeps Outperform Rating	MT
12/08/25	RBC Capital Adjusts Price Target on Legend Biotech to $77 From $75, Maintains Outperform Rating	MT
07/07/25	RBC Lowers Price Target on Legend Biotech to $75 From $78, Keeps Outperform Rating	MT
03/07/25	UBS Lowers Price Target on Legend Biotech to $54 From $60, Maintains Buy Rating	MT
14/05/25	Truist Securities Adjusts Legend Biotech Price Target to $71 From $88, Maintains Buy Rating	MT
07/01/25	RBC Trims Price Target on Legend Biotech to $84 From $86, Keeps Outperform Rating	MT
09/12/24	UBS Lowers Legend Biotech Price Target to $65 From $75, Maintains Buy Rating	MT
08/10/24	Redburn Initiates Legend Biotech at Buy With $86 Price Target	MT
15/07/24	TD Cowen Adjusts Legend Biotech Price Target to $67 From $71, Maintains Buy Rating	MT
17/06/24	Truist Securities Initiates Legend Biotech With Buy Rating, $88 Price Target	MT
24/05/24	HC Wainwright Adjusts Legend Biotech Price Target to $73 From $86, Maintains Buy Rating	MT
24/05/24	Deutsche Bank Starts Legend Biotech With Buy Rating	MT
14/05/24	HC Wainwright Adjusts Price Target on Legend Biotech to $86 From $87, Keeps Buy Rating	MT
14/05/24	RBC Adjusts Price Target on Legend Biotech to $86 From $85 on Model Updates, Maintains Outperform Rating	MT
17/04/24	Scotiabank Upgrades Legend Biotech to Sector Outperform From Sector Perform, Price Target is $65	MT
03/04/24	Cantor Fitzgerald Initiates Legend Biotech With Overweight Rating	MT
18/03/24	UBS Adjusts Legend Biotech Price Target to $81 From $76, Maintains Buy Rating	MT
13/03/24	Raymond James Starts Legend Biotech With Outperform Rating, $86 Price Target	MT
03/01/24	RBC Trims Price Target on Legend Biotech to $85 From $86, Keeps Outperform Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LEGEND BIOTECH CORPORATION					+224.53%
	ARGENX SE					+18.83%
	WUXI APPTEC CO., LTD.					+23.9%
	INSMED INCORPORATED					+32.54%
	BIONTECH SE					+26.82%
	WUXI BIOLOGICS (CAYMAN) INC.					+2.99%
	GENMAB A/S					-1.58%
	AKESO, INC.					+42.51%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+12.44%
	SUMMIT THERAPEUTICS INC.					+90.22%
	Average					+47.32%
	Weighted average by Cap.					+27.80%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.14USD

Average target price

71.85USD

Spread / Average Target

+224.53%

High Price Target

91.00USD

Spread / Highest target

+311.02%

Low Price Target

48.00USD

Spread / Lowest Target

+116.80%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

RBC Capital Markets
Oppenheimer
UBS
Truist Securities
Redburn Atlantic
HC Wainwright
Deutsche Bank Securities
Scotiabank
Cantor Fitzgerald
Raymond James
Barclays
Morgan Stanley
BTIG
William Blair & Co.
Daiwa Securities
BMO Capital
JPMorgan Chase
Piper Sandler
Cowen
Guggenheim